All In Biotech

Free tool

FAERS Monitor: Kybella

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206333 or its brand name (Kybella, Deoxycholic Acid). Reports on generic versions are filed under their own applications.

Reports

2,334

Serious

189

8% of reports

Hospitalization

51

Death reported

10

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective327
  • injection site swelling305
  • off label use287
  • swelling262
  • injection site pain191
  • facial paresis130
  • injection site nodule123
  • nerve injury115
  • hypoaesthesia110
  • injection site mass104
  • injection site induration86
  • contusion85
  • pain82
  • injection site bruising76
  • condition aggravated74

Reports by year received

View as table
YearReports
20131
20142
201539
2016354
2017212
2018392
2019314
2020219
2021219
2022203
2023208
202471
202573
202627

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
facial paresisSignal130343.7289.842,463
injection site noduleSignal123101.885.712,052
nerve injurySignal11594.278.710,404
injection site indurationSignal8660.248.94,916
injection site swellingSignal30536.032.410,343
injection site massSignal10425.421.12,412
swellingSignal26225.322.66,100
injection site bruisingSignal768.66.9504
contusionSignal858.06.5512
hypoaesthesiaSignal1106.65.5523
injection site painSignal1915.64.9730
off label useSignal2873.02.7385
drug ineffectiveSignal3272.22.0237
condition aggravatedSignal742.21.848
pain821.21.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.